Evaluation of the Frequency of the IL-28 Polymorphism (rs8099917) in Patients with Chronic Hepatitis C Using Zip Nucleic Acid Probes, Kerman, Southeast of Iran

  • Published : 2015.03.18


Polymorphisms in the region of the interleukin IL-28 gene on chromosome 19 have been related with clearance of hepatitis C virus (HCV), a major human pathogen responsible for chronic hepatitis, cirrhosis and hepatocellular carcinoma. About 3% of the world's population is infected with HCV. The long-term response to therapy is influenced by many host and viral factors, and recent evidence has indicated that some host genetic polymorphisms related to IL-28 are the most powerful predictors of virological response in patients with HCV. This study assessed frequency of the IL-28 polymorphism (rs8099917) in 50 patients (39 men and 11 women) with chronic hepatitis C using ZNA probe real time PCR new method. All patients were tested for genotype of HCV and the HCV viral load. In parallel, the levels of SGOT, SGPT and ALK enzymes were assessed. Treatment using Peg-interferon alpha with ribavirin was conducted for patients and subsequently samples were collected to detect any change in viral load or liver enzyme rates. The overall frequency of the TT allele is 74%, TG allele 20% and GG allele 6% and the percent of patients who had T allele was 84%. Clear reduction in viral load and liver enzymes was reported in patients with the T allele. Especially for genotype 1 which is relatively resistant to treatment, these alleles may have a role in this decline. In conclusion, we showed that IL-28 polymorphism rs8099917 strongly predicts virological response in HCV infection and that real-time PCR with Zip nucleic acid probes is a sensitive, specific and rapid detection method for detection of SNPs which will be essential for monitoring patients undergoing antiviral therapy.


Chronic hepatitis C;interleukin 28 polymorphism;zip nucleic acids;real time PCR


Supported by : Kerman University of Medical sciences


  1. Aberle SW, Kletzmayr J, Watschinger B, et al (2001). Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol, 39, 1972-4.
  2. Afshar RM, Mollaie HR (2012). Detection of HBV resistance to lamivudine in patients with chronic hepatitis B using Zip nucleic acid probes in Kerman, southeast of Iran. Asian Pac J Cancer Prev, 13, 3657-61.
  3. Aghasadeghi MR, Bahramali G, Sadat SM, et al (2011). Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment. Curr HIV Res, 9, 263-9.
  4. Al-Kubaisy WA, Obaid KJ, Noor NA, et al (2014). Hepatitis C virus prevalence and genotyping among hepatocellular carcinoma patients in Baghdad. Asian Pac J Cancer Prev, 15, 7725-30.
  5. Alvandi E, Koohdani F (2014). Zip nucleic acid: a new reliable method to increase the melting temperature of real-time PCR probes. J Diabetes Metab Disord, 13, 26.
  6. Aparicio E, Parera M, Franco S, et al (2010). IL28B SNP rs8099917 is strongly associated with pegylated interferonalpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One, 5, 13771.
  7. Bibert S, Roger T, Calandra T, et al (2013). IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med, 210, 1109-16.
  8. Callau Monje D, Braun N, Latus J, et al (2014). Successful antiviral triple therapy in a longstanding refractory hepatitis C virus infection with an acute kidney injury. Case Rep Nephrol, 2014, 308729.
  9. Chen C-H, Lee C-M, Tung W-C, et al (2010). Evolution of fulllength HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol, 52, 478-85.
  10. De Re V, Gragnani L, Fognani E, et al (2014). Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. Biomed Res Int, 2014, 710642.
  11. Fischer J, Bohm S, Muller T, et al (2013). Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection. PLoS One, 8, 77530.
  12. Harada N, Tamura S, Sugawara Y, et al (2014). Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C. PLoS One, 9, 90462.
  13. Hashemi M, Moazeni-Roodi A, Bahari A, et al (2012). A tetraprimer amplification refractory mutation system-polymerase chain reaction for the detection of rs8099917 IL28B genotype. Nucleosides Nucleotides Nucleic Acids, 31, 55-60.
  14. Jamalidoust M, Namayandeh M, Asaei S, et al (2014). Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol, 20, 5897-902.
  15. Keyvani H, Fazlalipour M, Monavari SH, et al (2012). Hepatitis C virus--proteins, diagnosis, treatment and new approaches for vaccine development. Asian Pac J Cancer Prev, 13, 5931-49.
  16. Labie D, Gilgenkrantz H (2010). [IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C]. Med Sci, 26, 225-6.
  17. Lazarus JV, Sperle I, Maticic M, et al (2014). A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infect Dis, 14, 16.
  18. Li PY, Zhou XJ, Yao L, et al (2012). Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. World J Gastroenterol, 18, 6481-8.
  19. Melis R, Fauron C, McMillin G, et al (2011). Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn, 13, 446-51.
  20. Moosavy SH, Froutan H, Andrabi Y, et al (2011). Frequency of YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. Med J Islamic Repub Iran, 25, 186-93.
  21. Noir Rg, Kotera M, Pons Bnd, et al (2008). Oligonucleotide- Oligospermine Conjugates (Zip Nucleic Acids): A Convenient Means of Finely Tuning Hybridization Temperatures. J Am Chem Soc, 9, 13500-5.
  22. Petruzziello A, Coppola N, Loquercio G, et al (2014). Distribution pattern of hepatitis C virus genotypes and correlation with viral load and risk factors in chronic positive patients. Intervirology, 57, 311-8.
  23. Riva E, Scagnolari C, Turriziani O, et al (2014). Hepatitis C virus and interferon type III (interferon lambda 3/interleukin 28B and interferon lambda 4): genetic basis of susceptibility to infection and response to antiviral treatment. Clin Microbiol Infect, 20, 1237-45
  24. Rosso C, Abate ML, Ciancio A, et al (2014). IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World J Gastroenterol, 20, 13146-52.
  25. Seaberg EC, Witt MD, Jacobson LP, et al (2014). Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men. J Viral Hepat, 21, 696-705.
  26. Tanaka Y, Ohira M, Tashiro H, et al (2014). Impact of alloimmune T cell responses on hepatitis C virus replication in liver transplant recipients. Hum Immunol, 75, 1259-67.
  27. Voirin E, Behr J-P, Kotera M (2007). Versatile synthesis of oligodeoxyribonucleotide oligospermine conjugates. Nature Protocols, 2, 1360-8.
  28. Yoshida EM, Sulkowski MS, Gane EJ, et al (2014a). Concordance of sustained virologic response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology, 61, 41-5
  29. Yoshida Y, Ikegami T, Yoshizumi T, et al (2014b). rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C: a case report. Transplant Proc, 46, 2426-9.
  30. Zekri AR, Hassan ZK, Bahnassy AA, et al (2012). Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus. Asian Pac J Cancer Prev, 13, 5433-8.
  31. Zhang L, Lu Q, Yang Z, et al (2014). Association of rs12979860 and rs8099917 polymorphisms in IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: A meta-analysis. Hum Immunol, 75, 1268-75